DHR

Boost ROI with home INR analyzers, recurring consumable sales, distribution partnerships, and local assembly to reduce tariff exposure and testing costs.Dublin, Oct.

Boost ROI by targeting services, computer vision, drug discovery, diagnostic labs and Asia-Pacific, supported by cloud integration and strategic partnershipsDublin, Oct.

Danaher (DHR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Danaher (NYSE:DHR) subsidiary Masimo received FDA clearance for AI-enabled atrial fibrillation detection in its Radius VSM wearable monitor.

Danaher came into this Q3 2026 report with the stock already grinding higher over the past three months. It then jumped another 4.3% to about $233.86 after the release. The move looks like a relief rally, yet the core story sits in the income statement.

Diversified science and technology company Danaher (NYSE:DHR) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.3% year on year to $6.55 billion. Its non-GAAP profit of $2.11 per share was 10% above analysts’ consensus estimates.

Danaher is back in focus as analysts edge price targets into the US$240 to US$255 range, with some models now centering around fair value of about US$244.14.

The conglomerate posted its latest set of quarterly earnings that morning.

Portfolio reshaping complete, management now pivots to organic growth and disciplined acquisitions to compound returns.

Revenue beat $6.6B with 8.5% growth; free cash flow hit $1.6B for the quarter.